s. aureus type 5 & 8 capsular polysaccharide conjugate
Vaccineexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
6
Phase 3
6
Phase 4
0
Earliest trial started Sep 1, 2003 (NCT00071214)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- Staphylococcus aureusImmunity, active
Staphylococcus aureus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- s. aureus type 5 & 8 capsular polysaccharide conjugate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00211965 | Phase 3 | Apr 1, 2005 | Nabi Biopharmaceuticals, Public Health England |
| NCT00211991 | Phase 3 | Apr 1, 2005 | Nabi Biopharmaceuticals, Vanderbilt University |
| NCT00211900 | Phase 3 | Mar 1, 2005 | Nabi Biopharmaceuticals |
| NCT00211926 | Phase 3 | Dec 1, 2004 | Nabi Biopharmaceuticals |
| NCT00211913 | Phase 3 | Jun 1, 2004 | Nabi Biopharmaceuticals |
| NCT00071214 | Phase 3 | Sep 1, 2003 | Nabi Biopharmaceuticals |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nabi Biopharmaceuticals | For profit | 6 | 6 | 1 | 2003 |
| Public Health England | Government | 1 | 0 | 1 | 2005 |
| Vanderbilt University | Academic/Hospital | 1 | 0 | 1 | 2005 |
3 organizations
Page 1 / 1